HUP0303765A2 - Atorvastatin-hemi-kalcium VII forma és eljárás az előállítására - Google Patents

Atorvastatin-hemi-kalcium VII forma és eljárás az előállítására

Info

Publication number
HUP0303765A2
HUP0303765A2 HU0303765A HUP0303765A HUP0303765A2 HU P0303765 A2 HUP0303765 A2 HU P0303765A2 HU 0303765 A HU0303765 A HU 0303765A HU P0303765 A HUP0303765 A HU P0303765A HU P0303765 A2 HUP0303765 A2 HU P0303765A2
Authority
HU
Hungary
Prior art keywords
preparation
form vii
new
atorvastatin hemi
calcium form
Prior art date
Application number
HU0303765A
Other languages
English (en)
Inventor
Judith Aronhime
Ramy Lidor-Hadas
Revital Lifshitz
Valerie Niddam
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of HUP0303765A2 publication Critical patent/HUP0303765A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

A találmány tárgya az atorvastatin-hemi-kalcium új formája, amit VIIformának jelölnek és új eljárások az előállítására. Az új formát úgyállítják elő, hogy az atorvastatinhemi-kalcium kristályos formájátetanolban szuszpendálják, előnyösen abszolút etanolban, és akeletkezett új formát izolálják. A találmány tárgya továbbá egymódszer a plazma alacsony sűrűségű lipoproteinszintjének csökkentésérehypercholesterinaemiában szenvedő vagy arra hajlamos betegekben és egykészítmény és kiszerelési forma a találmány alkalmazására. Ó
HU0303765A 2000-11-03 2001-11-05 Atorvastatin-hemi-kalcium VII forma és eljárás az előállítására HUP0303765A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24589700P 2000-11-03 2000-11-03
PCT/US2001/043947 WO2002041834A2 (en) 2000-11-03 2001-11-05 Atorvastatin hemi-calcium form vii

Publications (1)

Publication Number Publication Date
HUP0303765A2 true HUP0303765A2 (hu) 2004-03-01

Family

ID=22928549

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0303765A HUP0303765A2 (hu) 2000-11-03 2001-11-05 Atorvastatin-hemi-kalcium VII forma és eljárás az előállítására

Country Status (18)

Country Link
US (1) US6605636B2 (hu)
EP (1) EP1332130A4 (hu)
JP (1) JP2004513956A (hu)
KR (1) KR100704213B1 (hu)
CN (1) CN1535139A (hu)
AU (1) AU4150602A (hu)
CA (1) CA2426632C (hu)
CZ (1) CZ20031495A3 (hu)
HR (1) HRP20030442A2 (hu)
HU (1) HUP0303765A2 (hu)
IL (2) IL155734A0 (hu)
IS (1) IS6798A (hu)
MX (1) MXPA03003900A (hu)
NO (1) NO20031986D0 (hu)
PL (1) PL362472A1 (hu)
SK (1) SK6592003A3 (hu)
WO (1) WO2002041834A2 (hu)
ZA (1) ZA200303972B (hu)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
CA2623600A1 (en) * 2000-12-27 2002-07-04 Paul Adrian Van Der Schaaf Crystalline forms of atorvastatin
CN1524073A (zh) * 2001-06-29 2004-08-25 ����-�����ع�˾ ′R-(R*,R*)-2-(4-氟苯基)-β,δ-二羟基-5-(1-甲基乙基)-3-苯基-4-(苯基氨基）羰基-1H-吡咯-1-庚酸钙盐（2∶1）（阿托伐他汀）
US7074818B2 (en) 2001-07-30 2006-07-11 Dr. Reddy's Laboratories Limited Crystalline forms VI and VII of Atorvastatin calcium
CN100471836C (zh) * 2001-07-30 2009-03-25 雷迪实验室有限公司 托伐他汀钙晶型vi和vii
US20060020137A1 (en) * 2001-11-29 2006-01-26 Limor Tessler Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
AU2003217653A1 (en) * 2002-02-15 2003-09-09 Teva Pharmaceutical Industries Ltd. Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix
EP1465901A4 (en) * 2002-02-19 2006-02-01 Teva Pharma PROCESS FOR THE DESOLVATION OF ATORVASTATIN HEMI-CALCIUM SOLVATES AND OF ESSENTIALLY SOLVENT-FREE ATORVASTATIN HEMI-CALCIUM
EP1424324A1 (en) * 2002-11-28 2004-06-02 Teva Pharmaceutical Industries Limited Crystalline form F of Atorvastatin hemi-calcium salt
EP1572643A2 (en) * 2002-11-28 2005-09-14 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
FR2849029B1 (fr) 2002-12-20 2005-03-18 Lafon Labor Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.
US7790197B2 (en) 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
DE50306684D1 (de) * 2003-11-18 2007-04-12 Helm Ag Verfahren zur Herstellung von freifliessenden, pulverförmigen Atorvastatin-Adsorbaten
AU2005223491A1 (en) * 2004-03-17 2005-09-29 Ranbaxy Laboratories Limited Crystalline form of atorvastatin hemi calcium
WO2005092852A1 (en) 2004-03-17 2005-10-06 Ranbaxy Laboratories Limited Process for the production of atorvastatin calcium in amorphous form
JP2007536373A (ja) 2004-05-05 2007-12-13 ファイザー・プロダクツ・インク アトルバスタチンの塩形態
CA2573969C (en) * 2004-07-16 2014-02-04 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
CA2701710C (en) 2004-07-20 2013-08-27 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
WO2006037125A1 (en) * 2004-09-28 2006-04-06 Teva Pharmaceutical Industries Ltd. Process for preparing forms of atorvastatin calcium substantially free of impurities
EP1716114A1 (en) * 2004-10-18 2006-11-02 Teva Pharmaceutical Industries Ltd. Process for preparing amorphous atorvastatin hemi-calcium by dissolving the salt in an organic solvent which is a mixture of an alcohol and a ketone and/or an ester and removing the solvent
KR20070067175A (ko) 2004-10-28 2007-06-27 워너-램버트 캄파니 엘엘씨 무정형 아토르바스타틴 형성 방법
WO2006048894A1 (en) * 2004-11-05 2006-05-11 Morepen Laboratories Limited Novel crystalline forms of atorvastatin calcium and processes for preparing them.
SK288276B6 (sk) * 2005-04-08 2015-06-02 Egis Gyógyszergyár, Nyilvánosan Működő Részvénytársaság Spôsob prípravy kryštalickej polymorfnej formy hemivápenatej soli atorvastatínu
CA2547216A1 (en) 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
ATE466840T1 (de) 2005-11-21 2010-05-15 Warner Lambert Co Neue formen von är-(r*,r*)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-( -methylethyl)-3-phenyl-4- ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure magnesium
WO2007058664A1 (en) * 2005-11-21 2007-05-24 Teva Pharmaceutical Industries Ltd. Atorvastatin formulation
CN101370774A (zh) 2005-12-13 2009-02-18 特瓦制药工业有限公司 阿托伐他汀半钙的晶形及其制备方法
EP1810667A1 (en) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
MX2007013612A (es) * 2006-03-01 2007-12-10 Teva Pharma Proceso para preparar una forma cristalina de hemi-calcio de atorvastatina.
KR20080031487A (ko) * 2006-06-28 2008-04-08 테바 파마슈티컬 인더스트리즈 리미티드 아토르바스타틴의 결정형
WO2011028309A1 (en) 2009-09-04 2011-03-10 University Of Toledo PROCESSES FOR PRODUCING OPTICALLY PURE β-LACTONES FROM ALDEHYDES AND COMPOSITIONS PRODUCED THEREBY
KR20120011249A (ko) * 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
RU2021125455A (ru) 2013-11-15 2021-10-05 Экебиа Терапьютикс, Инк. Твердые формы { [5-(3-хлорфенил)-3-гидроксипиридин-2-карбонил]амино} уксусной кислоты, их композиции и применения
KR101720894B1 (ko) 2016-01-05 2017-03-30 김상우 무좀치료에 도움을 주는 건식 족욕기

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
CZ294740B6 (cs) * 1995-07-17 2005-03-16 Warner-Lambert Company Krystalická forma IV atorvastatinu nebo jeho hydrátu, farmaceutický přípravek obsahující tuto krystalickou formu IV atorvastatinu a její použití v lékařství
US6087511A (en) 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
DE60044884D1 (de) * 1999-11-17 2010-10-07 Teva Pharma Verfahren zur Herstellung einer polymorphen Form von Atorvastatin calcium
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
CA2623600A1 (en) * 2000-12-27 2002-07-04 Paul Adrian Van Der Schaaf Crystalline forms of atorvastatin
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
CN1524073A (zh) * 2001-06-29 2004-08-25 ����-�����ع�˾ ′R-(R*,R*)-2-(4-氟苯基)-β,δ-二羟基-5-(1-甲基乙基)-3-苯基-4-(苯基氨基）羰基-1H-吡咯-1-庚酸钙盐（2∶1）（阿托伐他汀）
CN100471836C (zh) * 2001-07-30 2009-03-25 雷迪实验室有限公司 托伐他汀钙晶型vi和vii

Also Published As

Publication number Publication date
NO20031986L (no) 2003-05-02
MXPA03003900A (es) 2005-02-17
ZA200303972B (en) 2004-08-23
KR100704213B1 (ko) 2007-04-10
IL155734A0 (en) 2003-11-23
SK6592003A3 (en) 2004-01-08
AU4150602A (en) 2002-06-03
WO2002041834A2 (en) 2002-05-30
JP2004513956A (ja) 2004-05-13
KR20040005854A (ko) 2004-01-16
US20020115709A1 (en) 2002-08-22
CN1535139A (zh) 2004-10-06
HRP20030442A2 (en) 2005-06-30
IS6798A (is) 2003-04-30
CA2426632A1 (en) 2002-05-30
CA2426632C (en) 2008-08-05
NO20031986D0 (no) 2003-05-02
EP1332130A4 (en) 2004-01-21
PL362472A1 (en) 2004-11-02
IL155734A (en) 2008-11-26
WO2002041834A3 (en) 2002-07-18
US6605636B2 (en) 2003-08-12
WO2002041834A8 (en) 2003-01-03
CZ20031495A3 (cs) 2004-01-14
EP1332130A2 (en) 2003-08-06

Similar Documents

Publication Publication Date Title
HUP0303765A2 (hu) Atorvastatin-hemi-kalcium VII forma és eljárás az előállítására
HUP0302693A2 (hu) Az alfa4-integrinek által közvetített sejttapadás inhibitoraiként hatásos új fenil-alanin származékok, eljárás elõállításukra és ilyen hatóanyagot tartalmazó gyógyászati készítmények
RS20060250A (en) 1-amino-2-oxy-substituted tetrahydronaphtalene derivatives, method for the production thereof, and their use as antiphlogistics
EP1205189A3 (en) Combination of a prostaglandin agonist and a HMG-CoA reductase inhibitor for the stimulation of bone growth
EA200700673A1 (ru) Твердая фармацевтическая композиция, содержащая донепезила гидрохлорид
NO20062656L (no) Fremgangsmate for fremstilling av statiner
MXPA05008183A (es) Proceso para preparar pirrolotriazina como inhibidores de cinasa.
TW200635905A (en) Processes for producing 4-aminoquinazolines
PL1670778T3 (pl) Przegrupowane pentanole, sposób ich wytwarzania i ich zastosowanie jako środków hamujących zapalenia
EA200601678A1 (ru) Новые имидазолы
MX2007005475A (es) Metabolitos de ciertos derivados de [1,4] diazepino [6,7,1-ij] quinolina y metodos de preparacion y uso de los mismos.
RS20070095A (en) Alkyliden-tetrahydronaphthalene derivatives, method for their production and their use as anti-inflammatory agents
MXPA03012045A (es) Proceso para preparar derivados del acido 7-amino sin 3,5-dihidroxi heptanoico a traves de derivados del acido 6-ciano sin 3,5-dihidroxi hexanoico.
HUP0204069A2 (hu) Új eljárás leflunomid előállítására és a leflunomid új kristályformája és ezt tartalmazó gyógyszerkészítmény
DE602007010725D1 (de) Verfahren und zwischenprodukt zur herstellung von donezepil
NO20073276L (no) Metode for fremstilling av aminoetoksybenzylalkoholer
HUP0500747A2 (hu) Eljárás fenszerin és analógjai előállítására
AU2002328835A1 (en) Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives, intermediates thereof and methods for their preparation
NO20016151L (no) Fremstilling av substituerte piperidin-4-oner
MY148499A (en) Substituted pyrrole derivatives
ATE299878T1 (de) Verfahren zur herstellung von azacycloalkanoylaminothiazolen
EE200100060A (et) (1H)benso[c]kinolisiin-3-ooni derivaatide sünteesi meetod
AU6578400A (en) Novel method for preparing benzoperhydroisoindole compounds
AU2003281220A1 (en) N-benzyl-3-phenyl-3-heterocyclyl-propionamide compounds as tachykinin and/ or serotonin reuptake inhibitors
EP1219714A3 (en) Method for production of geranylgeraniol and analogous compounds thereof by microorganisms

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees